Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN
This article was originally published in The Pink Sheet Daily
Executive Summary
Ability of novel anticoagulants to capture an extra indication in acutely ill patients currently treated with blockbuster Lovenox is now in doubt.